Drugs for Vulvovaginal Candidiasis Market Is Pegged at Around US$ 860 Million in 2019: QYR

QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.

Logo

Los Angeles, CA -- (SBWire) -- 04/13/2019 --The cell wall of Candida is a complex glycoprotein that depends on the biosynthesis of ergosterol. Azole compounds, found in antimycotic drugs, are believed to block ergosterol production, allowing topical antimycotics to achieve cure rates in excess of 80%. The only oral azole agent approved for this indication by the US Food and Drug Administration (FDA) is fluconazole, which also achieves a high cure rate. Therapeutic concentrations are found in vaginal secretions for at least 72 hours after the ingestion of a single 150-mg tablet.

Some women with recurrent candidal infections opt for treatment with over-the-counter (OTC) medications, which generally are highly effective for candidiasis. Preparations for intravaginal administration of butoconazole, clotrimazole, miconazole, and tioconazole are available OTC.

The classification of Drugs for Vulvovaginal Candidiasis includes Cream, Pessary and other. The proportion of Cream in 2017 is about 47.2%, and the proportion of Pessary in 2017 is about 34.1%.

The drugs for Vulvovaginal Candidiasis are Miconazole, Clotrimazole, Fluconazole, Econazole and Other, market share of Fluconazole is about 24.5% in 2017.

Drugs for Vulvovaginal Candidiasis is application in Hospital & Clinic and Pharmacy. The most of Drugs for Vulvovaginal Candidiasis is used in Pharmacy, and the market share in 2016 is about 59%.

The global Drugs for Vulvovaginal Candidiasis market was 770 million US$ in 2018 and is expected to 860 million US$ by the end of 2025, growing at a CAGR of 1.5% between 2019 and 2025.

This report studies the Drugs for Vulvovaginal Candidiasis market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Get PDF of this report template: https://www.qyresearch.com/sample-form/form/1092104/global-drugs-for-vulvovaginal-candidiasis-market

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Drugs for Vulvovaginal Candidiasis in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

Bayer

Perrigo

J & J

Pfizer

Bristol-Myers Squibb

Effik

Teva

Sanofi

Cisen Pharmaceutical

Kingyork Group

By the product type, the market is primarily split into

Cream

Pessary

Other

By the end users/application, this report covers the following segments

Hospital & Clinic

Pharmacy

Get Full Report Now at USD 3,350: https://www.qyresearch.com/settlement/pre/d909a561a8a30ca09a930dd34fe5b40f,0,1,Global%20Drugs%20for%20Vulvovaginal%20Candidiasis%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application

Benefits of Purchasing QY Research Report
- Analyst Support: Get you query resolved from our expert analysts before and after purchasing the report
- Customer's Satisfaction: Our expert team will assist with all your research needs and customize the report
- Inimitable Expertise: Analysts will provide deep insights about the reports
- Assured Quality: We focus on the quality and accuracy of the report

About Us: 
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Media Relations Contact

Rahul Singh
Director - Digital Marketing
QY Research, Inc.
1-626-295-2442
https://www.qyresearch.com/index/detail/1092104/global-drugs-for-vulvovaginal-candidiasis-market

View this press release online at: http://rwire.com/1195401